跳至主要内容
临床试验/NCT01164033
NCT01164033已完成1 期

An Open-Label, Randomized 3-Way Crossover, Study to Examine the Food-Effect on Pharmacokinetics of the Current Formulation and Relative Bioavailability of Two New Formulations for RO5045337 in Patients With Solid Tumors Including Lymphoma

Hoffmann-La Roche0 个研究点目标入组 76 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
76
主要终点
Examination of potential food-effect on pharmacokinetics of RO5045337

研究概览

简要总结

This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients, >/=18 years of age
  • Histologically confirmed solid tumor
  • Life expectancy of >/=12 weeks
  • ECOG performance status of 0 or 1
  • Adequate bone marrow, renal and hepatic function

排除标准

  • Patients receiving any other investigational agent or therapy administered with the intention to treat their malignancy within 28 days prior to study start
  • Patients with pre-existing gastro-intestinal disorder
  • Patients with uncontrolled intercurrent illness

研究组 & 干预措施

A

Active Comparator

干预措施: RO5045337 (Drug)

B

Experimental

干预措施: RO5045337 (Drug)

C

Experimental

干预措施: RO5045337 (Drug)

D

Experimental

干预措施: RO5045337 (Drug)

结局指标

主要结局

Examination of potential food-effect on pharmacokinetics of RO5045337

时间窗: 3 weeks

Evaluation of relative bioavailability of RO5045337

时间窗: 3 weeks

次要结局

  • Evaluation of safety and tolerability of RO5045337(3 weeks)
  • Evaluation of pharmacodynamics and biomarkers(3 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

A Study of RO5045337 in Patients With Solid Tumors | 临床试验